Commentary Dr Mehta's paper outlines many theoretical concepts which complement the more practical and pragmatic approach of our paper. More specifically, he agrees that ketone bodies may be important neonatal fuels especially for the brain, and that both neonatal hypoglycaemia and failure of ketone body production arise as a result of the failure of neonatal metabolic adaptation. In practical terms there is also agreement between us regarding the difficulties of definition, the avoidance of a rigid 'cut off' level, and the necessity for rapid accurate diagnostic methods without depending on reagent test strips. In terms of treatment of hypoglycaemia we agree that it is inadvisable to use high rates of glucose infusion or large intravenous boluses and that glucagon may be a useful additional treatment.
However, we feel that pragmatic recommendations are needed for the benefit of nursing and medical staff and that theoretical issues should be viewed in this context. Dr Mehta over emphasises the role of hyperinsulinism in the aetiology of neonatal hypoglycaemia. We have recently demonstrated that, especially in babies with disordered blood glucose homoeostasis, there are poor relationships among circulating blood glucose concentrations, plasma insulin concentrations, and glucose production rates. In addition, blood ketone body concentrations and plasma nonesterified fatty acid concentrations were not related to plasma insulin concentrations.1 2 This is not surprising in view of the many other factors which are essential for glucose and ketone body production, namely substrate availability, counter-regulatory hormones, and induction of enzyme systems.3
The main area of controversy regarding management appears to be in the treatment of the asymptomatic term infant whose blood glucose concentration is <2-0 mmol/l. Dr Mehta has already suggested that the presence of ketone bodies may protect the brain and our paper out- 
as low as <2-0 mmol/l. Therefore, it is not possible to claim that counter-regulation has failed if only blood glucose concentrations are measured. We feel that the presence of symptoms or the features of an underlying disorder are more important determinants of treatment than the blood glucose concentration alone, and would suggest that treating all asymptomatic term infants with blood glucose concentrations transiently below 2-0 mmol/l with intravenous glucose is over aggressive management.
If clinicians are not comfortable with blood glucose concentrations as low as this, we suggest that the first line of treatment should be to increase enteral feed volumes and frequency with formula supplementation of breast feeds, and check postprandial increases in blood glucose concentration, rather than to separate mother and baby and commence invasive management. In fact, we do not agree that enteral feeds should be withheld from hypoglycaemic infants who have previously tolerated milk feeds, as there is no scientific support for Dr Mehta's speculation in section c (1) (iii) and he has not examined the effect of withholding enteral feeds on ketone body production. Rather, milk contains more energy/ml than 10% dextrose and its high fat content will provide substrate for ketogenesis. In addition, there is published evidence that enteral feeding may stimulate glucagon release and ketone body production.4 5 We agree that adequate intakes of intravenous glucose or enteral milk prevent hypoglycaemia in most preterm infants, but point out that there is a high prevalence of hypoglycaemia in preterm infants who are fluid restricted. 5 In summary, we feel that it is inappropriate and potentially confusing to base the management of neonatal hypoglycaemia on hypotheses which are not fully scientifically tested. However, it should be noted that there is agreement between the two papers on the identification of groups at risk of failure of metabolic adaptation. Neonatal hypoglycaemia most commonly occurs when the normal processes of metabolic adaptation after birth fail to occur. These processes enable the healthy infant to meet two major metabolic challenges. First, the need to maintain an adequate circulating concentrations of glucose or alternative fuels to supply the body's organs, especially the brain, and second, the need to adapt to a new form of nutrition, namely intermittent feeding with milk. As the blood glucose concentration falls after the cutting of the umbilical cord and until milk feeding is established, the baby is entirely dependent upon its own resources to maintain fuel supply. Glycogenolysis is initiated as the initial counter-regulatory process. Once the glycogen stores are exhausted, however, substrates must be mobilised from body protein and fat stores so that gluconeogenesis can occur. These processes are induced by the counter-regulatory hormones (glucagon, catecholamines, growth hormone, and cortisol).
Although much is known of the basic biochemical processes which underlie these phenomena,5 6 
